Harvest Research Inc., ('s parent company) is one of the very few companies in this field that conducts its own research. Harvest Research has been working to isolate, study, develop and improve probiotic strains for more than 2 years at a public California University and more recently at its own state of the art Research Center.

A research study on the KE-99 strain was completed in May 2000. The results are now published under the title "Reduction of Sulfide, Ammonia Compounds, and Adhesion Properties of Lactobacillus casei strain KE99 in Vitro" in Current Microbiology Journal. The article outlines the methodology and results demonstrating KE-99 to be "highly adherent" compared to competitive strains, its superior sulfide and ammonia reduction properties and its ability to "inhibit and/or displace pathogens" including E.coli.

KE-99 is a probiotic supplement containing patented sub-species of lactobacillus casei, (the official name is Lactobacillus casei KE-99 strain). The KE-99 strain was evaluated at a public university in California and after two years of research KE-99 has proven to have superior absorption and functionality as a probiotic as compared to other strains. In addition to its functionality, KE-99 is well protected against moisture, heat and oxygen to ensure delivery of 10 billion casei cell per daily dosage.


The Lactobacillus casei sub-species, KE-99, was selected for its superior probiotic qualities. The primary effect of a probiotic is to reduce the likelihood of pathogenic organisms from establishing themselves and infecting the intestinal tract of a host. In order to accomplish this, the beneficial bacterium overwhelm the enteric sites to become the predominant bacterium present, and consume a significant portion of the nutrients which compromise or possibly eliminate the establishment and/or growth of any unwanted bacteria. (Competitive exclusion) In laboratory tests, however, KE-99 has demonstrated the ability to actually remove already established pathogenic bacteria in vitro (example: enterohemorrhagic E. coli 0157:H7). These bacteria often enter the intestinal tract via consumption of contaminated food and/or drink. This remarkable ability to reduce certain forms of pathogenic bacteria in vitro (currently being tested in vivo in swine) is one of the features that sets KE-99 apart as a superior probiotic.

A number of products on the market contain multiple bacterial strains. KE-99 was intentionally formulated with just one highly effective Lactobacillus casei KE-99 strain. A hardy single strain such as KE-99 has been shown to be much more effective than multiple strains because of its superior ability to attach to enteric sites and establish itself while multi-strains compete with each other and are often merely evacuated. The overall benefits of other strains of intestinal bacteria are well known, but they are meaningless unless they can actually attach to the intended site.